538 related articles for article (PubMed ID: 32032733)
1. Using human induced pluripotent stem cells (hiPSCs) to investigate the mechanisms by which Apolipoprotein E (APOE) contributes to Alzheimer's disease (AD) risk.
Raman S; Brookhouser N; Brafman DA
Neurobiol Dis; 2020 May; 138():104788. PubMed ID: 32032733
[TBL] [Abstract][Full Text] [Related]
2. Culture Variabilities of Human iPSC-Derived Cerebral Organoids Are a Major Issue for the Modelling of Phenotypes Observed in Alzheimer's Disease.
Hernández D; Rooney LA; Daniszewski M; Gulluyan L; Liang HH; Cook AL; Hewitt AW; Pébay A
Stem Cell Rev Rep; 2022 Feb; 18(2):718-731. PubMed ID: 33725267
[TBL] [Abstract][Full Text] [Related]
3. Genetic associations between cathepsin D exon 2 C-->T polymorphism and Alzheimer's disease, and pathological correlations with genotype.
Davidson Y; Gibbons L; Pritchard A; Hardicre J; Wren J; Tian J; Shi J; Stopford C; Julien C; Thompson J; Payton A; Thaker U; Hayes AJ; Iwatsubo T; Pickering-Brown SM; Pendleton N; Horan MA; Burns A; Purandare N; Lendon CL; Neary D; Snowden JS; Mann DM
J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):515-7. PubMed ID: 16543533
[TBL] [Abstract][Full Text] [Related]
4. Fragmentation of brain apolipoprotein E (ApoE) and its relevance in Alzheimer's disease.
Amponsah AE; Feng B; Guo R; Zhang W; He J; Kong D; Dong T; Ma J; Cui H
Rev Neurosci; 2020 Aug; 31(6):589-603. PubMed ID: 32364519
[TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of human induced pluripotent stem cell (hiPSC) lines from an Alzheimer's disease (ASUi001-A) and non-demented control (ASUi002-A) patient homozygous for the Apolipoprotein e4 (APOE4) risk variant.
Brookhouser N; Zhang P; Caselli R; Kim JJ; Brafman DA
Stem Cell Res; 2017 Oct; 24():160-163. PubMed ID: 29034886
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathogenesis of apolipoprotein E-mediated amyloidosis in late-onset Alzheimer's disease.
Tomiyama T; Corder EH; Mori H
Cell Mol Life Sci; 1999 Oct; 56(3-4):268-79. PubMed ID: 11212354
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer's disease pathology in APOE transgenic mouse models: The Who, What, When, Where, Why, and How.
Lewandowski CT; Maldonado Weng J; LaDu MJ
Neurobiol Dis; 2020 Jun; 139():104811. PubMed ID: 32087290
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease.
Zhao N; Liu CC; Qiao W; Bu G
Biol Psychiatry; 2018 Feb; 83(4):347-357. PubMed ID: 28434655
[TBL] [Abstract][Full Text] [Related]
9. ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease.
Li Y; Macyczko JR; Liu CC; Bu G
Neurobiol Aging; 2022 Jul; 115():20-28. PubMed ID: 35453035
[TBL] [Abstract][Full Text] [Related]
10. APOE4 is a Risk Factor and Potential Therapeutic Target for Alzheimer's Disease.
Ayyubova G
CNS Neurol Disord Drug Targets; 2024; 23(3):342-352. PubMed ID: 36872358
[TBL] [Abstract][Full Text] [Related]
11. APOE-amyloid interaction: Therapeutic targets.
Wisniewski T; Drummond E
Neurobiol Dis; 2020 May; 138():104784. PubMed ID: 32027932
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer's disease and apoE TR mouse cortex.
Arold S; Sullivan P; Bilousova T; Teng E; Miller CA; Poon WW; Vinters HV; Cornwell LB; Saing T; Cole GM; Gylys KH
Acta Neuropathol; 2012 Jan; 123(1):39-52. PubMed ID: 22020632
[TBL] [Abstract][Full Text] [Related]
13. Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer's disease?
Lozupone M; Imbimbo BP; Balducci C; Lo Vecchio F; Bisceglia P; Latino RR; Leone M; Dibello V; Solfrizzi V; Greco A; Daniele A; Watling M; Seripa D; Panza F
Alzheimers Dement; 2023 Jan; 19(1):353-368. PubMed ID: 35900209
[TBL] [Abstract][Full Text] [Related]
14. The pathogenic implication of abnormal interaction between apolipoprotein E isoforms, amyloid-beta peptides, and sulfatides in Alzheimer's disease.
Han X
Mol Neurobiol; 2010 Jun; 41(2-3):97-106. PubMed ID: 20052565
[TBL] [Abstract][Full Text] [Related]
15. [Apolipoprotein E4 and late-onset Alzheimer's disease].
Tamaoka A
Nihon Rinsho; 1994 Dec; 52(12):3257-65. PubMed ID: 7853720
[TBL] [Abstract][Full Text] [Related]
16. ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies.
Raulin AC; Doss SV; Trottier ZA; Ikezu TC; Bu G; Liu CC
Mol Neurodegener; 2022 Nov; 17(1):72. PubMed ID: 36348357
[TBL] [Abstract][Full Text] [Related]
17. Presenilin Is Essential for ApoE Secretion, a Novel Role of Presenilin Involved in Alzheimer's Disease Pathogenesis.
Islam S; Sun Y; Gao Y; Nakamura T; Noorani AA; Li T; Wong PC; Kimura N; Matsubara E; Kasuga K; Ikeuchi T; Tomita T; Zou K; Michikawa M
J Neurosci; 2022 Feb; 42(8):1574-1586. PubMed ID: 34987110
[TBL] [Abstract][Full Text] [Related]
18. APOE and Alzheimer's Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer's Pathogenesis.
Uddin MS; Kabir MT; Al Mamun A; Abdel-Daim MM; Barreto GE; Ashraf GM
Mol Neurobiol; 2019 Apr; 56(4):2450-2465. PubMed ID: 30032423
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein E and oxidative stress in brain with relevance to Alzheimer's disease.
Butterfield DA; Mattson MP
Neurobiol Dis; 2020 May; 138():104795. PubMed ID: 32036033
[TBL] [Abstract][Full Text] [Related]
20. The Role of APOE and TREM2 in Alzheimer's Disease-Current Understanding and Perspectives.
Wolfe CM; Fitz NF; Nam KN; Lefterov I; Koldamova R
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30587772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
